(RTTNews) - GSK plc (GSK, GSK. L) announced that China's National Medical Products Administration (NMPA) has approved Nucala (mepolizumab) as add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease or COPD characterised by raised blood eosinophils.